Miami Fort Lauderdale, FL, July 23, 2026 —

President Donald Trump has announced a new policy aimed at significantly altering the landscape of generic drug imports into the United States. Under the proposed plan, a 100% tariff is slated to be imposed on imported generic drugs beginning in August 2028. This tariff rate is scheduled to increase to 200% one year later.

The stated objective behind this policy is to incentivize the “reshore” of generic pharmaceutical production, encouraging manufacturers to establish or expand their operations within the United States. This move is intended to bolster domestic manufacturing capabilities in the pharmaceutical sector.

However, experts in the field have raised concerns regarding the potential ramifications of these tariffs. They warn that such measures could lead to substantial impacts on both the prices and the availability of generic medications. Generic drugs are a cornerstone of the U.S. healthcare system, accounting for more than 90% of all prescriptions filled nationwide.

Major global suppliers of generic drugs and their essential components to the U.S. market include countries such as India and China. The imposition of high tariffs on imports from these nations could disrupt existing supply chains.

The ultimate effect of this policy on American consumers remains a subject of analysis. It is expected to be contingent upon the detailed implementation specifics of the tariff structure and the subsequent responses from pharmaceutical companies and the broader healthcare industry.



Story summarized from the original created by Chantelle Lee on time.com, see more information here.

Media gallery

About The Author
SignalNews